LOGIN
ID
PW
MemberShip
2022-08-12 14:44
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Policy
Multidrug-resistant ¡®Zavicefta¡¯ applies for approval
by
Lee, Hye-Kyung
Mar 29, 2022 05:54am
Pfizer Korea has applied for the approval of its important treatment for severe gram-negative bacterial infection, ¡®Zavicefta.¡¯ Zavicefta, which received marketing authorization in 2016. is a combination drug that contains the third-generation ceftazidime. According to industry officials on the 28th, Pfizer Korea recently submitted a
Policy
Will the migraine tx Reyvow step on the same track
by
Lee, Tak-Sun
Mar 29, 2022 05:54am
Ildong Pharmaceutical's domestic copyrighted migraine drug Lasmiditan seems to be speeding up its benefit using the patent-approval linkage system. According to the industry on the 28th, the HIRA is recently listening to opinions on whether the migraine treatment Reyvow 50 & Reyvow100mg is eligible for medical care benefits through related co
Policy
BMS acute myeloid leukemia tx Onureg was approved
by
Lee, Hye-Kyung
Mar 29, 2022 05:54am
Onureg 200mg and Onureg 300mg, the first PO drugs were approved. Currently, Azacitidine-based AML treatments, which are approved in Korea, are injections with Celgene's Vidaza100mg, Boryung Pharmaceutical's Vizadakin and Samyang Holdings' Azalid 100mg and Azalid 150mg, and Onureg has become the first oral treatment. The MFDS (Director K
Policy
Will the separation of the Ministry of Health be promoted?
by
Lee, Jeong-Hwan
Mar 28, 2022 06:10am
Yoon Seok-yeol's presidential transition committee seems to be discussing the necessity of separating the Ministry of Health and integrating and absorbing the MFDS in the process of discussing the reorganization of the government after the inauguration of the next government. As the pandemic era became commonplace due to COVID-19, the role o
Policy
Govn¡¯t to introduce 460,000 courses of oral COVID-19 drugs
by
Kim, Jung-Ju
Mar 28, 2022 06:10am
The government will be introducing 460,000 courses of oral COVID-19 treatments by the end of next month. In principle, Paxlovid will be prescribed first, and Lagevrio, which has recently been approved for emergency use, should be used for patients who are restricted from using Paxlovid, such as users of contraindicated drugs. On the 25th,
Policy
The gov's all-out efforts to promote EUA for overseas drugs
by
Lee, Jeong-Hwan
Mar 28, 2022 06:10am
The government will make all-out efforts to expand the total amount of supply by expanding the production and import of regular medicines such as antipyretic painkillers and cold medicines used to alleviate COVID-19 symptoms. It will even review the emergency introduction of foreign drugs with the same composition as domestic licensed items,
Policy
Kymriah's benefit standard has been established
by
Lee, Tak-Sun
Mar 25, 2022 05:48am
Chimeric antigen receptor-T cell therapy, which can be effective only once by using cancer patient T cells, is expected to be given to patients after receiving health insurance benefits for the first time in Korea from April. Novartis' Kymriah will enter the benefit range a year after being approved in Korea. The HIRA announced that it wil
Policy
Yoon¡¯s transition team prepares for digital platform govnt
by
Lee, Jeong-Hwan
Mar 25, 2022 05:48am
President-elect Suk-Yeol Yoon¡¯s presidential transition committee announced a policy with the state-led public prescription system in mind. In the process of announcing the creation of a task force (TF) to bring the digital platform government into reality, the committee made a remark that it would be possible that the TF will establish
Policy
Corona tx Largevrio has been urgently approved
by
Lee, Hye-Kyung
Mar 24, 2022 05:54am
The MFDS (Director Kim Kang-rip) announced on the 23rd that it has decided on the EUA of Largevrio developed by Merck and imported by MSD Korea. Largevrio can be used in patients with severe liver and kidney disorders who are difficult to use injection-type treatments, and patients who cannot take Paxlovid, a conventional PO treatment, for
Policy
Ahn to tap on ¡°domestic production of Paxlovid generic¡±
by
Lee, Jeong-Hwan
Mar 24, 2022 05:54am
President-elect Suk-Yeol Yoon¡¯s transition committee is pursuing the manufacture of a generic version of the oral COVID-19 treatment, Paxlovid. The government plans to ask Pfizer whether it would be possible to produce generic copies of Paxlovid in exchange for royalties. At a press conference of the transition team that was held in
<
11
12
13
14
15
16
17
18
19
20
>